Eutilex

유틸렉스 · 263050

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$25.6M (₩35.3B)

Overview

Eutilex is a South Korean biotech, listed on KOSDAQ, that develops cancer immunotherapies, treatments that harness the body's own immune system to fight tumours.

Its pipeline includes cell-and-gene therapies (notably a next-generation CAR-T therapy targeting liver and other solid cancers) and antibody therapies designed to block immune suppression around tumours. Both lead programmes are currently in early-stage clinical trials in Korea.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$7.5M

▲ +8.1% YoY

Operating profit · FY2025

−US$13.7M

Loss narrowed

Net income · FY2025

−US$18.7M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$95.4K(₩131.7M)	US$6.9M(₩9.5B)	US$7.5M(₩10.3B)
Operating profit	−US$21.6M(−₩29.8B)	−US$19.2M(−₩26.5B)	−US$13.7M(−₩18.9B)
Net income	−US$20.5M(−₩28.3B)	−US$21.4M(−₩29.5B)	−US$18.7M(−₩25.8B)

Revenue

FY2023US$95.4K
FY2024US$6.9M
FY2025US$7.5M

Operating profit

FY2023−US$21.6M
FY2024−US$19.2M
FY2025−US$13.7M

Net income

FY2023−US$20.5M
FY2024−US$21.4M
FY2025−US$18.7M

Key ratios (FY2025)

ROE

-163.4%

Debt/Eq

161.0%

Op. margin

-183.8%

Net margin

-250.5%

Rev. YoY

▲ +8.1%

Why it matters

Alongside its biotech pipeline, Eutilex operates an IT services division, covering system integration, system management, and IT consulting, which it runs in parallel with its drug research and clinical activities.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?